NTRC Publications on Oncolines, SynergyFinder, ResidenceTimer, QuickScout:

  • Grobben et al. (2020) Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158. Journal of Structural Biology: X, , 4: 100014.
    https://doi.org/10.1016/j.yjsbx.2019.100014

References to Arginase Gold™, NFK GreenScreen:

  • Grobben et al. (2020) Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158. Journal of Structural Biology: X, 4: 100014. (Affiliation: NTRC)
    https://doi.org/10.1016/j.yjsbx.2019.100014
  • Seegers, N. et al. (2014) High-throughput fluorescence-based screening assays for tryptophan-catabolizing enzymes, Journal of Biomolecular Screening, 19 (9): 1266-1274. (Affiliation: NTRC)
    https://www.ncbi.nlm.nih.gov/pubmed/24870017

References to NTRC Technology Platforms:

  • Cordo et al. (2019) Phospho-Proteomic Profiling of T-Cell Acute Lymphoblastic Leukemia Identifies Specific Kinase Activation Signatures That Can Predict Response to Targeted Therapy, ASH Annual Meeting 2019, Orlando, December 07-10, Poster Abstract #4649. (Affiliation: Princess Máxima Center for Pediatric Oncology)
  • Conlon et al. (2019) Pre-clinical assessment of neratinib sensitivity and biomarkers of response, AACR-NCI-EORTC Conference Molecular Targets and Cancer Therapeutics, Boston, October 26-30, Abstract A046. (Affiliations: Dublin City University, Puma Biotechnology Inc.)
  • Rageot et al. (2019) (S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase, Journal of Medicinal Chemistry, 62 (13): 6241-6261. (Affiliations: University of Basel, PIQUR Therapeutics AG)
    https://doi.org/10.1021/acs.jmedchem.9b00525
  • Grünewald et al. (2019) Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models, International Journal of Cancer, 145 (5): 1346-1357. (Affiliation: Bayer AG)
    https://doi.org/10.1002/ijc.32224
  • Gentile et al. (2018) A Novel Interaction Between the TLR7 and a Colchicine Derivative Revealed Through a Computational and Experimental Study, Pharmaceuticals, 11 (1): 22. (Affiliation: University of Alberta)
    https://doi.org/10.3390/ph11010022
  • Bohnacker et al. (2017) Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention, Nature Communications, 8: 14683. (Affiliation: University of Basel)
    https://www.nature.com/articles/ncomms14683
  • Libouban et al. (2017) Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines, Oncotarget, 8 (24): 38309–38325. (Affiliations: Netherlands Cancer Institute, NTRC)
    https://doi.org/10.18632/oncotarget.16213
  • Wentsch et al. (2017) Optimized Target Residence Time: Type 1½Inhibitors for p38a MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-Spine, Angewandte Chemie International Edition, 56 (19): 5363-5367. (Affiliation: Universität Tübingen)
    https://doi.org/10.1002/anie.201701185
  • Canté-Barrett et al. (2016) MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia, Leukemia, 30: 1832-1843. (Affiliation: Erasmus MC)
    https://www.nature.com/articles/leu201683
  • Maia et al. (2015) Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model, Annals of Oncology, 26 (10): 2180-2192. (Affiliation: Netherlands Cancer Institute)
    https://doi.org/10.1093/annonc/mdv293
back to home